Skip to main content

Table 2 Mean pre-chemotherapy counts/mm 2 of tumor infiltrating lymphocytes subpopulations and CD68 for the whole group of patients and comparison between responding and non-responding patients

From: Tumor-infiltrating immune cell profiles and their change after neoadjuvant chemotherapy predict response and prognosis of breast cancer

TIL/mm 2Mean ± SD

Whole group

pCR

Non pCR

P a

CD3 cells

    

  Pre-CT

172.33 ± 334.50

324.33 ± 233.18

138.26 ± 345.70

0.0004

 

(n = 71)

(n = 13)

(n = 58)

 

  Post-CT

100.43 ± 117.43

94.98 ± 158.88

101.74 ± 106.58

0.25

 

(n = 88)

(n = 17)

(n = 71)

 

  Absolute variation

−78.46 ± 360.56

−259.59 ± 249.85

−37.87 ± 370.61

0.001

  (post-CT)-(pre-CT)

(n = 71)

(n = 13)

(n = 58)

 

  Relative variation, %

2459.63 ± 6403.11

281.52 ± 1242.71

2947.83 ± 6978.61

0.002

CD4 cells

    

  Pre-CT

67.33 ± 123.89

146.94 ± 161.77

48.44 ± 106.28

0.003

 

(n = 73)

(n = 14)

(n = 59)

 

  Post-CT

21.99 ± 69.64

58.38 ± 145.88

13.27 ± 27.66

0.31

 

(n = 88)

(n = 17)

(n = 71)

 

  Absolute variation

−52.28 ± 122.94

−119.93 ± 175.28

−36.23 ± 102.52

0.01

  (post-CT)-(pre-CT)

(n = 73)

(n = 14)

(n = 59)

 

  Relative variation, %

541.63 ± 1817.60

902.63 ± 3590.52

455.97 ± 1082.89

0.03

CD8 cells

    

  Pre-CT

30.25 ± 101.97

3.58 ± 12.93

36.03 ± 111.65

0.15

 

(n = 73)

(n = 13)

(n = 60)

 

  Post-CT

37.03 ± 66.65

65.61 ± 121.59

30.28 ± 43.95

0.35

 

(n = 89)

(n = 17)

(n = 72)

 

  Absolute variation

3.75 ± 110.74

39.42 ± 46.51

−3.97 ± 119.10

0.08

  (post-CT)-(pre-CT)

(n = 73)

(n = 13)

(n = 60)

 

  Relative variation, %

2650.38 ± 3563.74

4294.12 ± 4085.8

2294.24 ± 3373.26

0.08

FOXP3 cells

    

  Pre-CT

6.97 ± 17.98

8.37 ± 9.26

6.63 ± 19.53

0.01

 

(n = 68)

(n = 13)

(n = 55)

 

  Post-CT

16.51 ± 85.56

53.73 ± 190.42

7.60 ± 19.86

0.82

 

(n = 88)

(n = 17)

(n = 71)

 

  Absolute variation

0.4859 + 23.03

1.17 ± 27.44

0.32 ± 22.15

0.12

  (post-CT)-(pre-CT)

(n = 68)

(n = 13)

(n = 55)

 

  Relative variation, %

372.91 ± 1317.91

269.25 ± 901.21

397.411 ± 1404.04

0.08

CD20 cells

    

  Pre-CT

42.08 ± 83.05

92.82 ± 94.10

30.71 ± 76.73

0.000

 

(n = 71)

(n = 13)

(n = 58)

2

  Post-CT

14.17 ± 53.89

40.83 ± 119.40

7.79 ± 11.70

0.73

 

(n = 88)

(n = 17)

(n = 71)

 

  Absolute variation

−33.86 ± 78.03

−81.31 ± 86.12

−23.23 ± 72.71

0.01

  (post-CT)-(pre-CT)

(n = 71)

(n = 13)

(n = 58)

 

  Relative variation, %

296.45 ± 782.61

−45.09 ± 95.39

373.00 ± 847.17

0.002

CD68 cells

    

  Pre-CT

33.92 ± 45.09

55.65 ± 65.73

28.60 ± 37.48

0.12

 

(n = 61)

(n = 12)

(n = 49)

 

  Post-CT

39.08 ± 70.77

19.44 ± 23.52

43.51 ± 76.98

0.61

 

(n = 87)

(n = 16)

(n = 71)

 

  Absolute variation

−7.04 ± 58.85

−36.93 ± 62.27

0.27 ± 56.24

0.02

  (post-CT)-(pre-CT)

(n = 61)

(n = 12)

(n = 49)

 

  Relative variation, %

340.13 ± 1132.29

−1.03 ± 159.41

423.68 ± 1249.23

0.16

  1. aMann–Whitney U-test. CT, chemotherapy; n, number; pCR, pathological complete response; SD, standard deviation; TIL, tumor infiltrating lymphocytes.
Back to article page

Breast Cancer Research

ISSN: 1465-542X

Contact us